Dupont De Nemours Inc

DuPont de Nemours has launched the DuPont Sugar Separation Advisor, an interactive digital tool that helps sugar and sweetener manufacturers evaluate chromatographic separation opportunities and identify suitable DuPont AmberLite resins for further testing. The tool builds on decades of chromatography application expertise and years of experimental separation data, letting users select a target sugar or sweetener, add up to four additional sugars or impurities to represent their feed stream, and generate a predicted chromatogram that yields a qualitative separation assessment and candidate AmberLite resin suggestions. DuPont developed the platform in response to recurring customer questions involving sugars and sweeteners such as allulose, tagatose, sorbitol, oligosaccharides, xylose and inositol, and it could support applications ranging from high-fructose corn syrup and beet sugar processing to rare sugars, oligosaccharides, polysaccharides and sugar alcohols. The launch expands access to DuPont's chromatography expertise as the company focuses on innovation, productivity and growth across healthcare, water and industrial markets. In August, DuPont raised the midpoint of its full-year 2026 operating EBITDA and adjusted earnings guidance after second-quarter outperformance, now expecting net sales of $7.16-$7.19 billion, operating EBITDA of $1.75-$1.77 billion and adjusted earnings of $7.17-$7.32 per share.

Chemours, DuPont, and Corteva reached a settlement with North Carolina and 11 nearby local entities on September 9, 2026, agreeing to pay US$455 million over 15 years to resolve PFAS-related claims tied to Chemours' Fayetteville Works facility and other contamination issues. The agreement clears a significant portion of Chemours' legacy PFAS exposure and introduces a shared, net-present-value framework under the companies' existing US$4.00 billion cost-sharing cap. The North Carolina deal follows Chemours' June 2026 agreement with the U.S. EPA, which added US$90 million of PFAS mitigation and a US$22.5 million civil penalty, as well as settlements with New Jersey and a water district. Chemours' narrative projects $6.6 billion in revenue and $686.0 million in earnings by 2029, requiring 4.7% yearly revenue growth and a $990.0 million earnings increase from -$304.0 million today, with a $19.78 fair value implying 37% upside. The most pessimistic analysts assume only about 3.3% annual revenue growth and roughly US$556 million of earnings by 2029.

DuPont de Nemours has launched an end-to-end Direct Lithium Extraction portfolio comprising more than 20 technologies, drawing fresh attention as the company screens as undervalued with a fair value of about $172 per share versus a last close of $134.29. The share price has slipped around 6.8% over the past month and about 5.5% over the past quarter, even as the 1-year total shareholder return stands at roughly 46%. The most followed narrative rests on how earnings and margins could evolve, with accelerated growth in Electronics from AI-driven applications, advanced packaging, and high-performance computing expected to drive revenue expansion through 2025 and beyond. However, the stock currently trades on a P/E of 137.4x compared with 21.1x for peers and 25.2x for the US Chemicals industry, while a fair ratio of 29.1x suggests valuation risk if earnings do not track the upbeat forecast.

DuPont has launched an enhanced version of its WAVE PRO water treatment modeling tool that now integrates ultrafiltration, ion exchange resins, reverse osmosis, and nanofiltration in a single platform. The free, web-based tool helps municipal and industrial users design more accurate and efficient treatment systems for applications including drinking water, industrial utility water, wastewater, and seawater desalination. By connecting these core technologies, WAVE PRO reduces the need for separate simulations, minimizes manual data-entry errors, and captures interdependencies that affect system performance, such as how upstream ultrafiltration can improve downstream reverse osmosis. The platform supports collaboration with multi-user access and is compatible with Windows and iOS. DuPont Water Solutions' technologies purify more than 50 million gallons of water every minute across 112 countries.

The global flame retardant textile market is projected to grow from USD 10.78 billion in 2025 to USD 24.37 billion by 2035, at a compound annual growth rate of 8.52 percent. Protective clothing accounted for 41.60 percent of revenue in 2025, driven by occupational safety regulations in oil and gas, construction, and manufacturing, while transport textiles are expected to grow at the fastest rate of 12.82 percent. Natural fibers held the largest share at 42.60 percent, but synthetic fibers are forecast to expand at 11.12 percent CAGR. Aerospace led end-use segments with 38.50 percent share, and additive flame retardants dominated with 51.40 percent. North America held a 36.80 percent market share in 2025, with the U.S. market valued at USD 2.96 billion and projected to reach USD 5.80 billion by 2035. Europe's market is expected to grow at 8.49 percent CAGR to USD 6.94 billion, while Asia Pacific is anticipated to grow fastest at 10.36 percent. Key players include DuPont, Teijin, Toray Industries, and Huntsman Corporation.

DuPont de Nemours is one of the 10 best stocks to buy according to billionaire Jeffrey Talpins. The chemicals giant's shares have risen 53% over the past year and 14% year-to-date. RBC Capital maintained an Outperform rating, adjusting its price target to $51 from $48 in January, while Citi kept a Buy rating and raised its target to $170 from $68. In May, DuPont reported first-quarter net sales of $1.7 billion and adjusted earnings per share of $0.55, beating analyst estimates of $1.687 billion and $0.48, sending shares 8.4% higher on May 5th.

DuPont de Nemours has enacted a 1-for-3 reverse stock split, consolidating every three existing shares into one new share, and has been added to the Russell 1000 Defensive and Russell 1000 Value-Defensive Indices. The reverse split reduces the number of shares outstanding and proportionally increases the per-share price without changing the company's overall market value, while the board maintained a quarterly dividend of US$0.60 per share adjusted for the new share structure. The index inclusions may increase visibility with large index-tracking and rules-based funds, potentially broadening the investor base. Investors may want to monitor how trading volumes, price behavior, and fund ownership patterns evolve as these changes are absorbed by the market.

DuPont de Nemours declared a quarterly dividend of $0.60 per share on June 24, 2026, a 200% increase from its previous payout, marking one of the sharpest single-quarter dividend resets by a blue-chip industrial company this year. The dividend is payable on September 15, 2026, to shareholders of record as of August 31. The move follows a 58% rise in DuPont's stock over the past 52 weeks and a 13% gain year-to-date, with the company reporting first-quarter net sales of $1.7 billion, up 4%, and adjusted earnings per share of $0.55. DuPont also completed the Aramids divestiture on April 1 and announced a $275 million accelerated share repurchase, while full-year guidance points to about 4% organic sales growth. Analysts rate the stock a consensus Strong Buy with an average price target of $167.60, implying roughly 22% upside from current levels.

DuPont declared a quarterly dividend of $0.20 per share, a 200% increase from the previous $0.60, as part of this week's dividend activity that also saw increased payouts from Matson and AZZ, and declarations from Pfizer and AT&T. Matson raised its dividend to $0.38 from $0.36, a 5.6% increase, while AZZ increased its payout to $0.24 from $0.20, a 20% rise. Pfizer declared a dividend of $0.43 per share and AT&T declared $0.2775 per share. Looking ahead, Comcast and Sysco will have their ex-dividend dates on July 1 and July 2, respectively, for their upcoming payments.

DuPont has declared a quarterly dividend of $0.60 per share, a 200% increase from the prior dividend of $0.20. The forward yield is 1.74%. The dividend is payable on September 15 to shareholders of record as of August 31, with the ex-dividend date also on August 31.

DuPont has launched its new Tyvek APX chemical garment fabric in the ASEAN market at Thailand Safe@Work 2026 in Bangkok. The company describes Tyvek APX as the most advanced form of Tyvek material to date, offering enhanced breathability without compromising protection or durability. An independent physiological study by Empa validated the fabric's improved breathability, and global wear trials involving nearly 300 participants across various regions and applications showed a clear preference for the high-breathability material. Dave Kee, Global Business Director of DuPont Personal Protection, stated that the fabric addresses a key safety challenge by helping workers stay cooler in physically demanding environments.

Zacks Investment Research identifies DuPont de Nemours, Proto Labs, AMETEK, and ATI as compelling 3D printing stocks for long-term returns. DuPont strengthened its medical additive manufacturing capabilities through the 2023 acquisition of Spectrum Plastics Group, which uses proprietary processes like Projection Micro Stereolithography and Silicone 3D Printing. Proto Labs, which has manufactured over 700 million parts for more than 300,000 customers, launched an AI-enabled manufacturing platform called ProDesk in February 2026 to accelerate prototyping and production. AMETEK produces high-performance metal powders for additive manufacturing and expanded its precision scanning portfolio with the July 2025 acquisition of Faro Technologies. ATI offers end-to-end additive manufacturing capabilities from metal powder to finished parts and recently commissioned a state-of-the-art facility combining design, printing, heat treating, machining, and inspection for aerospace, defense, and space applications.

The global polymeric biomaterials market is projected to grow from USD 69.55 billion in 2024 to USD 267.25 billion by 2034, at a compound annual growth rate of 15.86%, according to a new report from Zion Market Research. The polylactic acid product segment held a dominant 28% revenue share in 2024, driven by its biodegradability and versatility in applications such as drug delivery and tissue engineering. By application, orthopedics led with a 29% share, fueled by rising demand for joint replacements and bone scaffolds. Asia-Pacific is expected to maintain its leading regional position, supported by healthcare expansion and investments in regenerative medicine in countries like China, Japan, and India. Key companies profiled include BASF, DuPont, Evonik Industries, and Corbion.